Study Registration (NCT07695688) Supports Imbed's Ongoing Effort to Address Biofilm — a Persistent Challenge Across Wound Care and Beyond

MIDDLETON, Wis., Oct. 1, 2026 /PRNewswire/ -- Imbed Biosciences, developer of the SAMatrix™ (Synthetic Antimicrobial Matrix) technology platform, today announced that its FDA-approved IDE study evaluating the safety of investigational DualGuard™ Silver-Gallium Matrix in split-thickness skin graft donor site wounds is now registered on ClinicalTrials.gov (NCT07695688). The study will be conducted at three American Burn Association (ABA)-verified burn centers. This milestone advances DualGuard's clinical development and reflects Imbed's broader pursuit of solutions to address the evolving challenges biofilm presents across healthcare.